Cas:31792-49-1 6-methyl-2-thiophen-2-ylquinoline-4-carboxylic acid manufacturer & supplier

Chemical Name:6-methyl-2-thiophen-2-ylquinoline-4-carboxylic acid

CAS.NO:31792-49-1

Synonyms:6-methyl-2-thien-2-ylquinoline-4-carboxylic acid

Molecular Formula:C₁₅H₁₁NO₂S

Molecular Weight:269.31800

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:469.2ºC at 760 mmHg

Density:1.344g/cm3

Index of Refraction:1.693

PSA:78.43000

Exact Mass:269.05100

LogP:3.96990

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 6-methyl-2-thien-2-ylquinoline-4-carboxylic acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-methyl-2-thien-2-ylquinoline-4-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-methyl-2-thien-2-ylquinoline-4-carboxylic acid Use and application,6-methyl-2-thien-2-ylquinoline-4-carboxylic acid technical grade,usp/ep/jp grade.

Related News: Ultimately there’s likely a broad mix of social, cultural and economic drivers at play, suggested Lona Sandon, program director of the Department of Clinical Nutrition in the School of Health Professions at the UT Southwestern Medical Center in Dallas. She was not part of the research. 6-methyl-2-thiophen-2-ylquinoline-4-carboxylic acid manufacturer Both were in Siberia, and both are Chinese nationals who had recently traveled to China. 6-methyl-2-thiophen-2-ylquinoline-4-carboxylic acid supplier Both were in Siberia, and both are Chinese nationals who had recently traveled to China. 6-methyl-2-thiophen-2-ylquinoline-4-carboxylic acid vendor Ultimately there’s likely a broad mix of social, cultural and economic drivers at play, suggested Lona Sandon, program director of the Department of Clinical Nutrition in the School of Health Professions at the UT Southwestern Medical Center in Dallas. She was not part of the research. 6-methyl-2-thiophen-2-ylquinoline-4-carboxylic acid factory One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively.